Updated Jul 16, 2026
Horn Margaret A has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $27.89M.
Margaret A. Horn is the Chief Operating Officer at Revolution Medicines, Inc., a clinical-stage precision oncology company. She has also held a similar role at Sangamo Therapeutics, Inc.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-17 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 29.6K | $160.12 | $4.74M |
| 2026-06-17 | RVMD | Revolution Medicines, Inc. | M — Option exercise | 25.7K | $26.50 | $682K |
| 2026-06-17 | RVMD | Revolution Medicines, Inc. | M — Option exercise | 3.3K | $29.80 | $98K |
| 2026-06-17 | RVMD | Revolution Medicines, Inc. | M — Option exercise | 573 | $40.74 | $23K |
| 2026-06-17 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 3.6K | $156.12 | $558K |
| 2026-06-17 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 60.4K | $160.17 | $9.67M |
| 2026-06-17 | RVMD | Revolution Medicines, Inc. | M — Option exercise | 44.9K | $29.80 | $1.34M |
| 2026-06-17 | RVMD | Revolution Medicines, Inc. | M — Option exercise | 15.5K | $40.74 | $633K |
| 2026-06-15 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 200 | $150.17 | $30K |
| 2026-06-15 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 4.6K | $149.64 | $688K |
| 2026-06-15 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 1.8K | $148.72 | $268K |
| 2026-06-15 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 500 | $147.27 | $74K |
| 2026-06-15 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 700 | $146.04 | $102K |
| 2026-06-15 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 885 | $145.15 | $128K |
| 2026-06-15 | RVMD | Revolution Medicines, Inc. | S — Open-market sale | 1.3K | $144.28 | $190K |
| 2026-06-15 | RVMD | Revolution Medicines, Inc. | M — Option exercise | 8.9K | $40.74 | $363K |
| 2026-06-15 | RVMD | Revolution Medicines, Inc. | M — Option exercise | 1.1K | $42.45 | $46K |
| 2026-03-19 | RVMD | Revolution Medicines, Inc. | S — Open-market sale [10b5-1] | 4.6K | $99.48 | $456K |
| 2026-03-04 | RVMD | Revolution Medicines, Inc. | A — Grant or award | 21.1K | $0.00 | |
| 2026-01-09 | RVMD | Revolution Medicines, Inc. | S — Open-market sale [10b5-1] | 1.7K | $102.90 | $175K |
Margaret A. Horn is the Chief Operating Officer at Revolution Medicines, Inc., a clinical-stage precision oncology company. She has also held a similar role at Sangamo Therapeutics, Inc.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 19 open-market sales ($27.89M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Horn Margaret A profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.